期刊文献+

他克莫司预防兔耳瘢痕增生的实验研究 被引量:5

Preventive effects of Tacrolimus on the rabbit ear hypertrophic scar model
下载PDF
导出
摘要 目的:研究他克莫司对兔耳瘢痕增生的影响。方法:选10只新西兰白兔雌雄各半,按本研究组建立的改良方法制作兔耳瘢痕模型,左耳为空白对照组涂凡士林软膏,右耳为实验组涂他克莫司软膏。伤后14天、21天、28天、35天及49天采集标本,行苏木精-伊红(HE)及Masson三色法染色,统计成纤维细胞密度,实时定量PCR(Real-time PCR)检测细胞外基质成分Ⅰ型胶原(collagen Ⅰ;ColI)和纤维连接蛋白(fibronectin;Fn),CD4+辅助性T细胞-2(Th2)产生的重要纤维化基因IL-4及参与T细胞早期活化的重要基因巨噬细胞集落刺激因子(macrophage colony stimulating factor;M-CSF)和肿瘤坏死因子-α(tumor necrosis factorα;TNF-α)的表达。结果:HE及Masson三色法染色可见实验组较对照组胶原沉积明显减少,PCR结果可见ColI、Fn、IL-4、M-CSF和TNF-α在实验组中的表达较对照组在各时间点均减少。结论:应用他克莫司可通过下调IL-4、M-CSF和TNF-α的表达来抑制兔耳瘢痕增生。 Objective To evaluate the preventive effect of tacrolimus on rabbit ear hypertrophic scar formation.Methods Ten New Zealand White rabbits were employed in this study.Ventral ear hypertrophic scar model was created according to our previous report.Experimental group contains all the right ear wounds and treated with tacrolimus ointment.The control group contains all the left ear wounds and treated with vaseline ointment.Both the groups were harvested on days 14,21,28,35 and 49 post wounding.Hematoxylin-eosin staining and Masson trichrome staining were performed to reveal differences in scar morphology.Real-time PCR was adopted to evaluate the expression of ColI,Fn,IL-4,M-CSF and TNF-α.Results The morphology had a large difference in the two groups.Compared with the control group,the fibroblast number in the treated group was significantly reduced(P0.01).The expression of ColI,Fn,IL-4,M-CSF and TNF-α were distinctly down-regulated in the treatment group.Conclusion Dealing with the post-wounding surface with tacrolimus may effectively suppress hypertrophic scar formation through down-regulating the expression of IL-4.、M-CSF and TNF-α.
出处 《中国美容医学》 CAS 2011年第5期756-759,共4页 Chinese Journal of Aesthetic Medicine
基金 国家自然科学基金资助(30801190) 陕西省攻关项目(2009k01-67)
关键词 瘢痕 免疫 他克莫司 Scar immune Tacrolimus
  • 相关文献

参考文献10

  • 1Shockman S,Paghdal KV,Cohen G. Medical and surgical management of keloids:a review [J]. J Drugs Dermatol,2010,9(10): 1249-1257.
  • 2Castagnoli C,Trombotto C,Ondei S,et al. Characterization of T-cell subsets infiltrating post-bum hypertrophic scar tissues[J]. Bums,1997, 23( 7-8):565-572.
  • 3Nunzi E,Parodi A,Rebora A.Immunofluorescence findings in haematoporphyrin-induced keloid [J]. Br J Dermatol,1983,108 (3): 263-266.
  • 4Morris DE ,Wu I ,Zhao El. ,et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies [J]. Plast Reconstr Surg, 1997,100(3): 674-681.
  • 5Tredget EE,Yang L,Delehanty M,et al. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal inJury[J]. J Interferon Cytokine Res, 2006, 26(3):179-189.
  • 6Wynn TA,cheever AW,Jankovic D,et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection[J]. Nature, 1995, 376(6541 ):594-596.
  • 7Thomas A,Wynn. Firbotic disease and the TH1/TH2 paradigm [J]. Nat Rev Immunol,2004,4(8): 583-594.
  • 8Duncan JI,Thomson AW,Muir IF. Topical cyclosporin and T lymphocytes in keloid scars[J].Br J Dermatol, 1991,124(1 ): 109.
  • 9曾海峰,韩晓霞,刘蓓,鲁开化,郭树忠,夏炜.他克莫司抑制兔耳瘢痕增生的作用及其机制研究[J].中国美容医学,2011,20(1):68-70. 被引量:12
  • 10Kim A,DiCarlo J,Cohen C,et al. Are keloids really "gli-loids"?: High-level expression ofgli-1 oncogene in keloids [J]. J Am Acad Dermatol,2001,45(5):707-711.

二级参考文献9

  • 1Traci A.Wilgus.Immune cells in the healing skin wound:Influential players at each stage of repair[Y].Pharmacol Rcs,2008,58:112-116.
  • 2Dumont FJ.FK506,an immunosuppressant targeting calcineurin function[J].Curr Med Chem,2000,7(7):731.
  • 3Morris DE,Wu I,Zhso LL,et al.Acute and chronic animal models for excessive dermal scarfing:quantitative studies[J].Plast Reeonstr Surg,1997,100:674-681.
  • 4Singer AJ,Clark RA.Cutaneous wound healing[J].N Engl J Med,1999,341(10):738-746.
  • 5Toshikazu Kondo,Yuko Ishida.Molecular pathology of wound healing[J].Forensic Sci Int,2010,203(1-3):93-98.
  • 6Niessen FB,Spanwen PH,Schalkwijk J,et al.On the nature of hypertrophic scafs and keloids:a review[J].Plast Reconstr Surg,1999,104(5):1435-1458.
  • 7Wynn TA.Cellular and molecular mechanisms of fibrosis[J].J Pathol,2008,214(2):199-210.
  • 8Willem M,vandec Veer,Monica C T et al.Potential cellular and molecular causes of hypertrophicscar formation[J] Burns,2009,35:15-29.
  • 9程飚,付小兵,盛志勇.免疫因素在瘢痕形成和发展中的作用[J].中国临床康复,2002,6(4):472-473. 被引量:12

共引文献11

同被引文献132

  • 1刘海兵,唐丹,曹海燕,李奎成.温哥华瘢痕量表的信度研究[J].中国康复医学杂志,2006,21(3):240-242. 被引量:260
  • 2王小影.丹参霜与超声波联合治疗预防增生性瘢痕[J].中华医学美学美容杂志,2006,12(6):366-366. 被引量:8
  • 3王齐,聂芳菲,赵霞,秦泽莲.periostin在过度增生性瘢痕的表达及其与TGF-β1和受体的相关性[J].中华整形外科杂志,2007,23(3):229-232. 被引量:21
  • 4蔡宏,顾瑛,曾晶,李韶然,王颖,施东雯,张露勇.光动力学疗法对兔耳增生性瘢痕作用的初步研究[J].中华整形外科杂志,2007,23(5):425-427. 被引量:9
  • 5Bran GM, Goessler UR, Hormann K, et al. Keloids : current con- cepts of pathogenesis (review) [ J ]. Int J Mol Med, 2009, 24(3) :283-293.
  • 6Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids [ J ]. J Drugs Dermatol, 2011,10 ( 5 ) :468-480.
  • 7Arima J, Ogawa R, Iimura T, et al. Relationship between Keloid and Hypertension[ J]. J Nippon Med Sch, 2012,79(6) :494-495.
  • 8Adhami VM, Syed DN, Khan N, et al. Dietary flavonoid fisetin : a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management[J]. Biochem Pharmacol, 2012,84(10) :1277-1281.
  • 9Shegogue D, Trojanowska M. Mammalian target of rapamycin posi- tively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway[ J]. J Biol Chem, 2004,279 ( 22 ) : 23166-23175.
  • 10Ong CT, Khoo YT, Mukhopadhyay A, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars [ J ]. Exp Dermatol, 2007,16(5) :394-404.

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部